Replies to post #1082 on Bristol Myers Squibb (BMY)

[DewDiligence]

1Q22 CC transcript:

https://www.fool.com/earnings/call-transcripts/2022/04/29/bristol-myers-squibb-bmy-q1-2022-earnings-call-tra/

[DewDiligence]

BMY acquires TPTX for $76.00 cash—a 122% premium to yesterday’s close:

https://www.businesswire.com/news/home/20220603005198/en

As a result of the acquisition, BMY is reducing 2022 non-GAAP EPS guidance by $0.08 plus a charge for in-process R&D to be determined later. (BMY’s prior 2022 non-GAAP EPS guidance was $7.44-7.74.)

[DewDiligence]

BMY 2Q22 results:

https://news.bms.com/news/corporate-financial/2022/Bristol-Myers-Squibb-Reports-Second-Quarter-Financial-Results-for-2022/default.aspx

2022 non-GAAP EPS guidance remains $7.44-7.74.